Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-09. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Syd Lawrence (1923 in Wilmslow–1998), a talented trumpet player and bandleader Michael Rother (born 1950), founder of Krautrock legends Neu!, lived in Wilmslow as a 9-year-old Christopher Gayford (born 1963 in Wilmslow), a conductor, currently with the City of Sheffield Youth Orchestra Doves, an Indie rock band, met at Wilmslow High School in the 1980s. Their song "Black and White Town" was inspired by Wilmslow and its contradicting 'rich-poor' divide The 1975, a pop rock band formed in 2002 at Wilmslow High School, included guitarist Adam Hann, drummer and lead vocalist Matty Healy, bassist Ross MacDonald, and George Daniel a later drummer.
The IDF also said that it killed two Lebanese militants attempting to infiltrate the border and plant an explosive at an IDF post. Two Israeli soldiers were killed and nine others were injured in Hezbollah attacks in the vicinity of the Lebanese border. Three rockets launched by Hezbollah to Metula caused fires and damaged electric infrastructure. The IDF said that its jets struck more than a hundred Hezbollah rocket launchers and other Hezbollah sites in its heaviest air strikes since the Israel–Hezbollah conflict started in October 2023. An Israeli strike in al-Haniyeh wounded four people. The Lebanese National News Agency reported that Israeli airstrikes targeted Mahmoudieh, Ksar al-Aroush, and Birket Jabbour. On 20 September, an Israeli strike in the Dahieh suburb of Beirut killed Ibrahim Aqil, the acting commander of the elite Redwan Force and other personnel including Ahmad Mahmoud Wahabi, a senior commander of Hezbollah while they were in a meeting. At least 45 people were killed including Aqil, Wahabi, another 14 high-ranking Hezbollah militants, three children, and seven women, while 68 people were injured. Heavy rocket fire was reported afterward in northern Israel. Hezbollah claimed that its Katyusha rockets struck the IDF base in Meron. Hezbollah also said that it targeted Israeli airbases, intelligence bases, and a tank. On 21 September, the IDF claimed to have "almost completely dismantled" Hezbollah's military chain of command. The IDF claimed that it destroyed thousands of rocket launchers. Four people were wounded in Israeli strikes.
Y-90, used for treating lymphoma (2.7 days) I-131, used for thyroid function tests and for treating thyroid cancer (8.0 days) Sr-89, used for treating bone cancer, intravenous injection (52 days) Ir-192, used for brachytherapy (74 days) Co-60, used for brachytherapy and external radiotherapy (5.3 years) Cs-137, used for brachytherapy and external radiotherapy (30 years) Tc-99, product of the decay of technetium-99m (221,000 years)
== Medical uses == Orforglipron is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
Substrate-level phosphorylation: 2 ATP from glycolysis + 2 ATP (directly GTP) from Krebs cycle Oxidative phosphorylation 2 NADH+H+ from glycolysis: 2 × 1.5 ATP (if glycerol phosphate shuttle transfers hydrogen atoms) or 2 × 2.5 ATP (malate-aspartate shuttle) 2 NADH+H+ from the oxidative decarboxylation of pyruvate and 6 from Krebs cycle: 8 × 2.5 ATP 2 FADH2 from the Krebs cycle: 2 × 1.5 ATP Altogether this gives 4 + 3 (or 5) + 20 + 3 = 30 (or 32) ATP per molecule of glucose These figures may still require further tweaking as new structural details become available. The above value of 3 H+ / ATP for the synthase assumes that the synthase translocates 9 protons, and produces 3 ATP, per rotation. The number of protons depends on the number of c subunits in the Fo c-ring, and it is now known that this is 10 in yeast Fo and 8 for vertebrates. Including one H+ for the transport reactions, this means that synthesis of one ATP requires 1 + 10/3 = 4.33 protons in yeast and 1 + 8/3 = 3.67 in vertebrates. This would imply that in human mitochondria the 10 protons from oxidizing NADH would produce 2.72 ATP (instead of 2.5) and the 6 protons from oxidizing succinate or ubiquinol would produce 1.64 ATP (instead of 1.5). This is consistent with experimental results within the margin of error described in a recent review. The total ATP yield in ethanol or lactic acid fermentation is only 2 molecules coming from glycolysis, because pyruvate is not transferred to the mitochondrion and finally oxidized to the carbon dioxide (CO2), but reduced to ethanol or lactic acid in the cytoplasm.
Sources: en.wikipedia.org
This definition is much more practical, but an equilibrium constant defined in terms of concentrations is dependent on conditions. In particular, equilibrium constants for species in aqueous solution are dependent on ionic strength, as the quotient of activity coefficients varies with the ionic strength of the solution. The values of the standard free energy change and of the equilibrium constant are temperature dependent. To a first approximation, the van 't Hoff equation may be used.
=== Canada === In March 2002, Whirlpool announced it would close its last manufacturing facility in Canada, the Inglis plant in Montmagny, Quebec, by 2004, terminating 500 workers and shifting production to facilities in Tulsa, Oklahoma and Oxford Mississippi.
Any drug (including a biological product for human use), medical device for human use, human food additive, color additive, electronic product, or any other article subject to regulation under the FD&C Act (21CFR50.3) Toxicity
=== Cardiovascular health === The Food and Drug Administration (FDA) granted the following health claim for soy: "25 grams of soy protein a day, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease." One serving of 1 cup (~240 mL) of soy milk, for instance, contains 6 or 7 grams of soy protein. An American Heart Association (AHA) review of a decade long study of soy protein benefits did not recommend isoflavone supplementation. The review panel also found that soy isoflavones have not been shown to reduce post-menopausal "hot flashes" and the efficacy and safety of isoflavones to help prevent cancers of the breast, uterus or prostate is in question. AHA concluded that "many soy products should be beneficial to cardiovascular and overall health because of their high content of polyunsaturated fats, fiber, vitamins, and minerals and low content of saturated fat". Other studies found that soy protein consumption could lower the concentration of low-density lipoproteins (LDL) transporting fats in the extracellular water to cells.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.